Liquidia Technologies: Gates Foundation PRI: US$10 million

Liquidia Technologies announced the Bill & Melinda Gates Foundation made a US$10 million program-related investment (PRI) to support the company’s “development and commercialization of safer and more effective vaccines and therapeutics. This follows recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative (MVI).” Neal Fowler, CEO of Liquidia, said, “We are delighted the Gates Foundation has decided to join an outstanding group of investors that share our confidence in the potential of PRINT technology to improve vaccine delivery and effectiveness. As the field of vaccines continues to grow, success will be defined by our ability to produce and deliver highly efficacious therapies in quantities and costs that will support the global demand.”

http://www.liquidia.com/press/Liquidia_Gates_PR.pdf